Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4831 in HFpEF: target engagement, safety and tolerability
2018-002895-42Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) and heart failure with mid-range ejection fraction (HFmrEF) comparing AZD4831 with Placebo (2 arms). Primary endpoint: Change from baseline in target engagement marker. Started Sep 2018; status: terminated.
02
Drugs
mitiperstat
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure with mid-range ejection fraction (HFmrEF)
Beyond the preview
Go deeper on 2018-002895-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002895-42.